PropertyValue
?:abstract
  • In SARS-CoV-2 infection, the viral load peaks early setting off a cascade of immune dysregulation that persists well after viral clearance Severe COVID-19 is marked by aberrant innate and adaptive immune responses with an abnormal cytokine profile and a prolonged illness course with multisystem organ dysfunction Antiviral treatments have yet to show benefit later in critical illness Taken together, this raises the concern that a purely antiviral treatment approach may be insufficient A number of immunomodulatory strategies are being tested, including corticosteroids, cytokine and anti-cytokine therapies, small molecule inhibitors, and cellular therapeutics The only drug to date to show a mortality benefit for COVID-19 in a randomized control trial is dexamethasone, but there remains uncertainty about which patients may benefit most and longer-term complications including secondary infections Here we review the immune dysregulation of severe COVID-19, the existing data behind various immunomodulatory strategies, and consider future directions of study
is ?:annotates of
?:creator
?:journal
  • Clin_Infect_Dis
?:license
  • unk
?:publication_isRelatedTo_Disease
?:source
  • WHO
?:title
  • Immunomodulation as Treatment for Severe COVID-19: a systematic review of current modalities and future directions
?:type
?:who_covidence_id
  • #939557
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/txae6t9q>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/txae6t9q>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all